Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362400 · ClinicalTrials.gov registry record · Phase 2
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
NCT01362400 is a Phase 2 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 226 participants.
The verdict
NCT01362400, a Phase 2 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the impact of IPI-504 in combination with docetaxel to placebo in combination with docetaxel on life expectancy in patients with Non Small Cell Lung cancer (NSCLC). Docetaxel is an approved chemotherapy for NSCLC. An additional goal of the study is to determine the effect of IPI-504, in combination with docetaxel, verses placebo in, combination with docetaxel, on the growth of cancer
Interventions
- DRUG IPI 504 plus Docetaxel
- DRUG Placebo plus Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01362400
The ClinicalTrials.gov registry entry for NCT01362400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IPI 504 plus Docetaxel is the first listed.
NCT01362400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01362400 about?
NCT01362400 is a clinical study titled "A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer". The purpose of this study is to compare the impact of IPI-504 in combination with docetaxel to placebo in combination with docetaxel on life expectancy in patients with Non Small Cell Lung cancer (NSCLC). Docetaxel is an approved chemotherapy for NSCLC. An additional goal of the study is to determin...
What is the current status of trial NCT01362400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2011-05. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01362400?
The interventions under investigation include: IPI 504 plus Docetaxel (DRUG), Placebo plus Docetaxel (DRUG).
Who is sponsoring clinical trial NCT01362400?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.